Literature DB >> 14668056

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

Joachim Gullbo1, Malin Wickström, Marcus Tullberg, Hans Ehrsson, Rolf Lewensohn, Peter Nygren, Kristina Luthman, Rolf Larsson.   

Abstract

Recently, we presented a series of melphalan containing di- and tripeptides with high cytotoxic activity and J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester) was identified as one of the most interesting compounds. It was speculated that the increased activity compared to melphalan itself, demonstrated both in vitro and in vivo, resided in increased transport over the tumour cell membrane and/or hydrolytic cleavage and liberation of melphalan inside the cells. Indeed, overexpression of hydrolytic enzymes like peptidases, esterases and proteases has been described in several types of human malignancies, thus providing a target for selective chemotherapy. In this work, the details of the increased activity was further investigated and potential tumour selectivity is discussed. The intracellular delivery of melphalan is investigated in detail using peptidase resistant dipeptide derivatives, by enzyme inhibitors and probes for enzymatic activity and by studying the time dependency of drug effect as well as intracellular drug concentrations (cellular pharmacokinetics). The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intracellular release of the alkylating unit (i.e. free melphalan) in cells with high enzymatic activity. The maximum intracellular melphalan concentration following J1 exposure was reached already after 15 min, thereafter declining with a half-life of approximately 1 h. This rapid intracellular loading resulted in less reduction of activity for J1 than for melphalan and six other standard drugs when human tumour cell lines were exposed to the drugs for a limited time (simulating short half-life in vivo). Peptidase inhibitors inhibited the activity and intracellular release of melphalan, and dipeptide derivatives designed to resist the action of peptidases was less active than the corresponding normal dipeptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668056     DOI: 10.1080/10611860310001647140

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  15 in total

1.  Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  J Pharm Pharm Sci       Date:  2012       Impact factor: 2.327

2.  In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authors:  Dharminder Chauhan; Arghya Ray; Kristina Viktorsson; Jack Spira; Claudia Paba-Prada; Nikhil Munshi; Paul Richardson; Rolf Lewensohn; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-04-12       Impact factor: 12.531

3.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

4.  Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Authors:  Kristina Viktorsson; Carl-Henrik Shah; Therese Juntti; Petra Hååg; Katarzyna Zielinska-Chomej; Adam Sierakowiak; Karin Holmsten; Jessica Tu; Jack Spira; Lena Kanter; Rolf Lewensohn; Anders Ullén
Journal:  Mol Oncol       Date:  2016-01-02       Impact factor: 6.603

5.  First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Authors:  Åke Berglund; Anders Ullén; Alla Lisyanskaya; Sergey Orlov; Hans Hagberg; Bengt Tholander; Rolf Lewensohn; Peter Nygren; Jack Spira; Johan Harmenberg; Markus Jerling; Carina Alvfors; Magnus Ringbom; Eva Nordström; Karin Söderlind; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2015-11-10       Impact factor: 3.850

6.  Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Authors:  Joachim Gullbo; Elin Lindhagen; Saadia Bashir-Hassan; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Manuel De La Torre; Kristina Luthman; Rolf Larsson
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

7.  In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.

Authors:  Sara Strese; Saadia Bashir Hassan; Ebba Velander; Caroline Haglund; Martin Höglund; Rolf Larsson; Joachim Gullbo
Journal:  Oncotarget       Date:  2017-01-24

8.  In vitro and in vivo activity of melflufen (J1)in lymphoma.

Authors:  Maryam Delforoush; Sara Strese; Malin Wickström; Rolf Larsson; Gunilla Enblad; Joachim Gullbo
Journal:  BMC Cancer       Date:  2016-04-04       Impact factor: 4.430

9.  Preclinical activity of melflufen (J1) in ovarian cancer.

Authors:  Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo
Journal:  Oncotarget       Date:  2016-09-13

Review 10.  Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.

Authors:  Fortunato Morabito; Giovanni Tripepi; Enrica Antonia Martino; Ernesto Vigna; Francesco Mendicino; Lucio Morabito; Katia Todoerti; Hamdi Al-Janazreh; Graziella D'Arrigo; Filippo Antonio Canale; Giovanna Cutrona; Antonino Neri; Massimo Martino; Massimo Gentile
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.